Regeneron has announced that the European Commission (EC) has approved Libtayo (cemiplimab ... Trial groups (ENGOT), and NRG Oncology-Japan. Patients were of a median age of 51 years old ...

Regeneron's oncology platform is poised to be a significant growth driver in the next decade. Read why REGN stock remains a ...

With a market cap of $62.4 billion, Regeneron Pharmaceuticals ... the company’s products include EYLEA, Dupixent, Libtayo, Praluent, REGEN-COV, and Kevzara. More Top Stocks Daily: Go behind ...

Sanofi and Regeneron's latecomer checkpoint inhibitor Libtayo has largely been protected from heavyweight competition in its first niche markets, but now looks set to for a toe-to-toe contest with ...

Approval based on Phase 3 trials demonstrating Dupixent significantly reduced itch and hives compared to placebo In the U.S., there are more than ...

Dupixent is the first new targeted therapy for CSU in a decade and is already approved in several countries, including Japan and Brazil ... Scientific Officer at Regeneron, and a principal ...

U.S. forces and Japanese police will hold a joint patrol in Okinawa Prefecture this week after a number of sexual assault cases involving U.S. military personnel came to light last year, a Japanese ...

In a report released on April 11, Salveen Richter from Goldman Sachs maintained a Buy rating on Regeneron (REGN – Research Report), with a price target of $917.00. The company’s shares closed ...

Biocon Biologics has reached a settlement with Regeneron, allowing the launch of Yesafili, its biosimilar eye drug, in the US by the second half of 2026. Approved by the USFDA as an ...